Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. More Details
Adequate balance sheet with moderate growth potential.
Share Price & News
How has Aldeyra Therapeutics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALDX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: ALDX's weekly volatility has decreased from 12% to 6% over the past year.
7 Day Return
1 Year Return
Return vs Industry: ALDX exceeded the US Biotechs industry which returned 24.6% over the past year.
Return vs Market: ALDX exceeded the US Market which returned 35.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Aldeyra Therapeutics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StIs Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Popular Amongst Institutions?
5 months ago | Simply Wall StHow Many Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Shares Did Insiders Buy, In The Last Year?
Is Aldeyra Therapeutics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: ALDX ($8.9) is trading below our estimate of fair value ($202.82)
Significantly Below Fair Value: ALDX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: ALDX is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ALDX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ALDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ALDX is overvalued based on its PB Ratio (3.4x) compared to the US Biotechs industry average (2.8x).
How is Aldeyra Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ALDX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: ALDX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ALDX's is expected to become profitable in the next 3 years.
Revenue vs Market: Insufficient data to determine if ALDX's revenue is forecast to grow faster than the US market.
High Growth Revenue: Insufficient data to determine if ALDX's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ALDX is forecast to be unprofitable in 3 years.
How has Aldeyra Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALDX is currently unprofitable.
Growing Profit Margin: ALDX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALDX is unprofitable, and losses have increased over the past 5 years at a rate of 23.1% per year.
Accelerating Growth: Unable to compare ALDX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (68.2%).
Return on Equity
High ROE: ALDX has a negative Return on Equity (-30.91%), as it is currently unprofitable.
How is Aldeyra Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ALDX's short term assets ($147.1M) exceed its short term liabilities ($11.1M).
Long Term Liabilities: ALDX's short term assets ($147.1M) exceed its long term liabilities ($10.1M).
Debt to Equity History and Analysis
Debt Level: ALDX's debt to equity ratio (12.1%) is considered satisfactory.
Reducing Debt: ALDX's debt to equity ratio has increased from 6.3% to 12.1% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALDX has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ALDX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Aldeyra Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALDX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALDX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALDX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Todd Brady (49 yo)
Dr. Todd C. Brady, M.D., Ph.D., is a Director at F-star Therapeutics, Inc since November 20, 2020. He has been the Chief Executive Officer and President of Aldeyra Therapeutics, Inc. since January 2012. Dr...
CEO Compensation Analysis
Compensation vs Market: Todd's total compensation ($USD2.42M) is above average for companies of similar size in the US market ($USD1.72M).
Compensation vs Earnings: Todd's compensation has been consistent with company performance over the past year.
Experienced Management: ALDX's management team is considered experienced (3 years average tenure).
Experienced Board: ALDX's board of directors are considered experienced (7.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 67.7%.
Aldeyra Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Aldeyra Therapeutics, Inc.
- Ticker: ALDX
- Exchange: NasdaqCM
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$512.918m
- Shares outstanding: 57.63m
- Website: https://www.aldeyra.com
Number of Employees
- Aldeyra Therapeutics, Inc.
- 131 Hartwell Avenue
- Suite 320
- United States
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company’s lead product candidate is reproxalap, an ophthalmi...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/31 06:19|
|End of Day Share Price||2021/07/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.